Search the Newsreel

Precision's leadership changes arrive as hepatitis B, DMD programs advance

Precision BioSciences has announced significant changes to its senior leadership team to support the advancement of its lead clinical programs for chronic hepatitis B (PBGENE-HBV) and Duchenne muscular dystrophy (PBGENE-DMD). Alex Kelly will transition from CFO to the newly created COO role, while Naresh …

Precision BioSciences Inc - Detailed Introduction, Company Background, Business Scope, Financial Data, and Market Performance | TradingKey

Precision BioSciences Inc. (DTIL) is a clinical-stage gene editing company utilizing its proprietary ARCUS platform to develop in vivo gene editing candidates for genetic and infectious diseases. The article details the company's background, including its pipeline programs like PBGENE-HBV and PBGENE-3243, corporate information, key …

Octagon Capital Advisors LP Acquires 318,737 Shares of Precision BioSciences, Inc. $DTIL

Dhunseri Tea reports ₹59 lakh profit on asset sales, declares ₹2 dividend

Precision BioSciences Inc (DTIL) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides historical dividend and stock split information for Precision BioSciences Inc (DTIL). It shows that the company has not distributed any dividends over the past five years and lists several merger-type stock splits that occurred on February 9, 2024.

Precision BioSciences Market Sentiment

This article analyzes the market sentiment for Precision BioSciences (DTIL) based on analyst consensus, short interest, options flow, and insider activity. Analysts show a "Buy" consensus with an average price target significantly above the current price, despite 9.1% short interest. The article also provides …

DTIL|Precision BioSciences Inc|Price:7.290|Chg%:-0.040

Precision BioSciences Inc (DTIL) closed at $7.29, down 0.55%, with a market cap of $188.10M. The company's fundamentals are considered healthy with high growth potential, and its valuation is seen as fairly valued by TradingKey. Analysts rate DTIL a "Strong Buy" with a target …

Lynx1 Capital Management LP Acquires Additional Shares in Precision BioSciences Inc

Lynx1 Capital Management LP has increased its stake in Precision BioSciences Inc (NASDAQ: DTIL) by acquiring an additional 405,498 shares, bringing its total holdings to 1,390,611 shares. This strategic move, valued at $8.59 per share, highlights Lynx1 Capital's continued interest in the biotechnology sector …

Lynx1 Capital discloses 5.4% Precision BioSciences (DTIL) ownership in Schedule 13G

Lynx1 Capital Management LP and Weston Nichols have disclosed a beneficial ownership of 5.4% in Precision BioSciences, Inc. (DTIL) through a Schedule 13G filing. This ownership amounts to 1,390,611 shares of common stock, with shared voting and dispositive power. The percentage is calculated based …

Strength Seen in Precision BioSciences (DTIL): Can Its 12.3% Jump Turn into More Strength?

Precision BioSciences enters Russell 2000, lifting visibility with investors

DTIL Forecast — Price Target — Prediction for 2027

Why Is Precision BioSciences Stock Gaining Wednesday? - Precision BioSciences (NASDAQ:DTIL)

Bullish: Analysts Just Made A Notable Upgrade To Their Precision BioSciences, Inc. (NASDAQ:DTIL) Forecasts

Precision BioSciences Reports First Quarter 2026 Financial Results and Provides Business Update

Precision BioSciences (DTIL) Q4 Profit Of US$19.2m Challenges Ongoing Loss Narrative

Precision BioSciences (DTIL) Surges After Strong Q4 Earnings Bea

Precision BioSciences, Inc.'s (NASDAQ:DTIL) one-year returns climbed after last week's 24% gain, institutional investors must be happy

Precision BioSciences, Inc. Share Price Live Today – NASDAQ:DTIL Stock Price, Chart, News, History

DTIL Stock: Price, Forecast, Financials & AI Analysis

What date does Precision BioSciences's (DTIL) report Earnings - Earnings Calendar & Announcement

Should I buy Precision BioSciences (DTIL)

Precision BioSciences (DTIL) Earnings Date and Reports 2026 $DTIL